Dyne Therapeutics, Inc. (DYN)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Dyne Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 17.68 | 18.33 | 17.40 | 18.07 | 2,359,190 |
| Nov 5, 2026 | 18.78 | 18.78 | 17.33 | 17.36 | 3,203,982 |
| Nov 4, 2026 | 18.57 | 19.00 | 17.94 | 18.54 | 3,649,306 |
| Nov 3, 2026 | 17.53 | 18.14 | 17.31 | 18.05 | 2,815,819 |
| Nov 2, 2026 | 16.81 | 17.35 | 16.71 | 17.30 | 2,907,341 |
| Oct 30, 2026 | 16.97 | 17.20 | 16.34 | 16.69 | 1,449,832 |
| Oct 29, 2026 | 17.20 | 17.59 | 16.75 | 17.04 | 1,427,329 |
| Oct 28, 2026 | 16.30 | 17.11 | 16.11 | 16.98 | 2,178,109 |
| Oct 27, 2026 | 15.80 | 16.97 | 15.73 | 16.94 | 3,002,014 |
| Oct 26, 2026 | 15.64 | 16.02 | 15.53 | 15.72 | 1,741,944 |
| Oct 23, 2026 | 15.91 | 15.91 | 15.31 | 15.62 | 2,134,279 |
| Oct 22, 2026 | 15.98 | 16.34 | 15.67 | 15.77 | 2,052,551 |
| Oct 21, 2026 | 16.33 | 16.73 | 15.91 | 16.07 | 1,789,809 |
| Oct 20, 2026 | 15.27 | 16.56 | 15.14 | 16.27 | 3,405,269 |
| Oct 19, 2026 | 14.45 | 15.38 | 14.45 | 15.23 | 3,346,179 |
| Oct 16, 2026 | 15.21 | 15.49 | 14.13 | 14.25 | 2,860,512 |
| Oct 15, 2026 | 15.15 | 15.47 | 15.04 | 15.29 | 2,074,626 |
| Oct 14, 2026 | 15.11 | 15.41 | 14.71 | 15.04 | 2,195,905 |
| Oct 13, 2026 | 15.97 | 15.99 | 15.28 | 15.30 | 3,341,605 |
| Oct 12, 2026 | 16.54 | 16.76 | 15.73 | 15.96 | 2,915,117 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Kerr Douglas | Head of R&D and CMO | Grant/Award | 12.0K | -- | Oct 20, 2026 |
| Kerr Douglas | Head of R&D and CMO | Grant/Award | 8.0K | -- | Oct 20, 2026 |
 Posner Brian S | Director | Purchase | 2.5K | $40.0K | Oct 2, 2026 |
| Kerr Douglas | Head of R&D and CMO | Sale | 1.3K | $24.4K | Sep 8, 2026 |
 Friedl-Naderer Johanna | Chief Commercial Officer | Sale | 185 | $3.5K | Sep 8, 2026 |
 Cox John | CEO & President | Sale | 5.7K | $106.8K | Sep 8, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
T. Rowe Price Investment Management, Inc. | 30.9M | 16.5% | 13F |
T. Rowe Price Investment Management, Inc. · also on 13F· may incl. warrants· filed May 2026 | 30.8M | 16.4% | 13G |
BlackRock, Inc. | 12.4M | 6.6% | 13F |
JANUS HENDERSON GROUP Ltd. · may incl. warrants· filed Sep 2026 | 12.0M | 6.4% | 13G |
Jupiter Topco LLC | 12.0M | 6.4% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2026 | 11.5M | 6.1% | 13G |
FMR LLC | 11.2M | 6.0% | 13F |
FMR LLC · also on 13F· joint filing· may incl. warrants· filed Aug 2026 | 11.2M | 6.0% | 13G |
STATE STREET CORP | 7.5M | 4.0% | 13F |
Orbis Allan Gray Ltd | 7.0M | 3.7% | 13F |
Insiders
- Kerr DouglasHead of R&D and CMO
- Posner Brian SDirector
- Friedl-Naderer JohannaChief Commercial Officer
- Cox JohnCEO & President
- Rhodes Jason PDirector
- Lucera ErickChief Financial Officer
- Kersten DirkDirector
- Greene Barry EDirector
- HURWITZ EDWARDDirector
- Lubner David CharlesDirector
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases.
The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
13F filers report 192.09M shares, more than the 187.39M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.
US30d Avg
2.54M
60d Avg
2.95M
90d Avg
2.86M